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Abstract Periodontitis and rheumatoid arthritis (RA) are
common chronic inflammatory conditions and share many
clinical and pathologic features. There is evidence to suggest
that similar profiles of cytokine genotypes and their coding
proteins are involved in the pathogenesis of periodontitis and
RA. In particular, constitutive overproduction of pro-
inflammatory cytokines, including tumor necrosis factor-
alpha (TNF-α) and interleukin-6 (IL-6), has been implicated
to play a pathologic role in the two inflammatory diseases.
Results from studies with animal and human subjects have
suggested an improvement of periodontal inflammatory con-
dition after treatment with TNF-α inhibitors. Likewise, IL-6
receptor inhibition therapy has been suggested to have an
effect on control of periodontal inflammation in patients with
RA. In the present review, we provide an overview of studies
showing the pathological role of cytokines in the linkage
between periodontitis and RA, and further summarize the
current studies assessing the effect of cytokine targeted ther-
apy on periodontal condition.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease
characterized by chronic inflammation and joint tissue de-
struction, leading to functional disability. The prevalence of
RA is estimated to be approximately 0.5 % in the world [1].
Periodontitis represents a chronic inflammatory disease affect-
ing tooth-supporting tissues, and is initiated by oral anaerobic
bacteria. Similarities in the clinical and pathological features
have been suggested between periodontitis and RA [2–6]. It
has been reported that patients with RA are more likely to
have periodontitis [3, 7–10], whereas patients with moderate-
to-severe periodontitis have a higher prevalence of RA than
those without periodontitis [10–12]. These bidirectional rela-
tionships between the two diseases might be related to the
common host immune response as well as similar
pathobiology.
Despite the differences in initiating etiological mecha-
nisms, several polymorphisms of genes encoding cytokines
have been proposed to affect connective tissue and bone
metabolism in both diseases [4]. In addition, there is accumu-
lating evidence to support the notion that both periodontitis
and RA manifest as a result of persistent high levels of pro-
inflammatory cytokines and their related molecules [5]. In
particular, constitutive overproduction of tumor necrosis
factor-alpha (TNF-α) and interleukin-6 (IL-6) has been sug-
gested as one of the most common confounding factors for the
two inflammatory diseases [6]. Moreover, novel therapeutic
strategies based on pro-inflammatory cytokine blockade have
been developed for the treatment of RA. Several studies with
animals and the patients have evaluated the efficacy of
cytokine-targeted therapy on periodontal inflammation and
destruction levels.
The present review focuses on the evidence regarding the
pathologic role of specific cytokine genotypes and their cod-
ing proteins in the pathogenesis of periodontitis and RA.
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Furthermore, we summarize the studies assessing the effect of
cytokine targeted therapy on periodontal inflammatory condi-
tion in patients with RA (Table 1).
Common Genetic Components
Case-Control Study
Susceptibility to periodontitis is influenced by genetic and
environmental factors, as well as periodontopathic bacteria
[13]. The evidence for genetic susceptibility to periodontitis
comes from twin studies showing that half of the population
variance in periodontitis is attributable to genetic factors [14,
15]. It is also established that genetic and environmental
factors participate in the pathogenesis of RA [16]. A family
association study indicated that the standardized incidence
ratio for RA in offspring of affected parents was 3.02 [17].
The genetic contribution to RA in the population accounted
for approximately 60 % of the variation in liability to disease
in a twin study [18]. These findings suggest that genetically
determined variances in host immune responses are important
determinants for susceptibility for both periodontitis and RA.
The first approach to find common genetic risk factors was
conducted in a case-control study with Danish white adults,
documenting that frequencies of IL-1A -889 and +4845, and
IL-1B -511 and +3954 genotypes were similar among local-
ized and generalized aggressive periodontitis (LAgP and
GAgP), juvenile idiopathic arthritis, RA, and healthy control
groups [19]. However, the differences in cytokine levels be-
tween the IL-1 genotypes were observed within all four dis-
ease groups, but not within the control group [19]. These
findings suggest a shared genetic background of IL-1 for
cytokine profiles of patients with AgP and RA. Another
case-control study with Japanese adults demonstrated that
the distributions of IL-1B +3954 genotypes and haplotypes
of IL-1A +4845 and IL-1B +3954 were unique to patients
with RA and periodontitis compared with those with peri-
odontitis and healthy individuals [20]. These observations
are supported by the results of another study evaluating 16
Table 1 Studies assessing the effect of cytokine-targeted therapy on periodontal condition in patients with rheumatoid arthritis (RA)
Authors Targets
(Biologics)
Subjects (Number) Parameters Summary
Pers et al. [80] TNF (IFX) 2 groups: RAwith IFX (20) and
without IFX (20).
Of these, RAwith IFX (9)
evaluated before and after 6 weeks.
PI, MGI, PBI, PD, AL IFX increased MGI and PBI, decreased
AL, and did not affect PD.
Ortiz et al. [81] TNF and TNFR
(IFX, ETN, ADA)
4 groups: TNFI+Sc/Rp (10), TNFI
(10), Sc/Rp (10), and non-TNFI
non-Sc/Rp (10), evaluated
before and after 6 weeks.
PI, GI, BOP, PD, CAL,
serum TNF-α
TNF inhibitors decreased GI, BOP, PD,




TNF (IFX) 3 groups: RAwith IFX (10) and
without IFX (10), and healthy
control (10).
PI, GI, BOP, PD, Clinical
AL, GCF TNF-α
IFX decreased GI, BOP, clinical AL,




TNF (IFX) 5 groups: RAwith IFX (10), RA
without IFX (12), PA (12), SSc
(12,) and healthy control (10).




TNF (IFX, ADA) 2 groups: RAwith IFX (9) and
RAwith ADA (7), evaluated
before and after 30 days.
PI, GI, BOP, PPD, CAL,
saliva/GCF IL-1βIL-8,
MCP-1
TNF blockers decreased GI, %BOP,
GCF levels of IL-1β and IL-8, and
saliva levels of IL-8 and MCP-1.
Kobayashi
et al. [85]
TNF (ADA) 1 group: RAwith ADA (20) evaluated
before and after 3 months.
PI, GI, BOP, PD, CAL,
serum TNF-αIL-6, MMP-3
ADA decreased GI, %BOP, PD, and
serum levels of TNF-α, IL-6, and




IL-6R (TCZ) 2 groups: RAwith TCZ (28) and
without TCZ (27), evaluated
during 8 weeks.
PI, GI, BOP, PD, CAL,
serum TNF-αIL-6, MMP-3
TCZ showed a greater decrease in
GI, %BOP, PD, CAL, and serum
levels of IL-6 and MMP-3.
TNF Tumor necrosis factor, IFX Infliximab, TNFR TNF receptor, ETN Etanercept, ADA Adalimumab, IL-6R Interleukin-6 receptor, TCZ Tocilizumab,
TNFI TNF inhibitor,
Sc/Rp Scaling and root planing, PA Psoriatic arthritis, SSc Systemic sclerosis, PI Plaque index, MGI Modified gingival index, PBI Papillary bleeding
index, PD Probing depth,
AL Attachment loss, GI Gingival index, BOP Bleeding on probing, GCF Gingival crevicular fluid, CAL Clinical attachment level, FMBS Full-mouth
bleeding score,
PPD Probing pocket depth, IL-1β Interleukin-1β, MCP-1 Monocyte chemoattractant protein-1, MMP-3 Matrix metalloproteinase-3
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cytokine gene polymorphisms encoding IL-1, IL-2, IL-4, IL-
6, IL-10, TNF-α, and transforming growth factor-β 1 [21].
Pathologic expression of genes in individuals with periodon-
titis and RA might be reflected in peripheral blood mononuclear
cells (PBMCs), because of their close relation to the pathogenesis
of inflammatory diseases.Microarray analyses have revealed that
53 differentially expressed candidate genes were identified in
PBMCs from individuals with LAgP. Of these, 14 genes were
associated with cytokine responses including IL-1B and IL-6
[22], which is consistent with the results of the above-mentioned
genetic studies [20, 21]. The validation of these genetic data
using real-time reverse transcription-polymerase chain reaction
(RT-PCR) confirmed that Toll-like receptor 2 (TLR2) gene ex-
hibited a higher expression by PBMCs from individuals with
LAgP and those with RA compared with healthy controls [24].
These findings are supported by the results of other studies [23,
24] demonstrating an increased expression of TLR2 in
periodontitis-affected gingival tissue as well as blood monocytes
and synovial tissue macrophages from patients with RA. It is,
therefore, suggested that elevated gene expressions for IL-1B and
TLR2 may constitute a common risk factor for periodontitis and
RA. However, there has been some difficulty identifying the
disease-specific genes, because no direct and simple correlation
has been obtained between PBMCs transcript and protein levels
of IL-1A, -1B, -1 receptor antagonist (IL-1RN), IL-6, IL-10,
TNFA, and TNF receptor I and II, determined by RT-PCR and
sensitive enzyme-linked immunosorbent assay (ELISA) [25].
Epigenetic variability is a crucial mechanism in regulation
of the production of pro-inflammatory cytokines relevant to
the pathogenesis of inflammatory diseases such as RA and
periodontitis [26]. Two major epigenetic mechanisms of in-
terest are the post-transcriptional modification of histone pro-
teins in chromatin and methylation of DNA which are regu-
lated by distinct, but coupled, pathways. Analysis of bisulfite
genomic sequences has revealed that a total of 19 CpG motifs
were identified from -1200 bp to +27 bp in IL-6 promoter
region, and that the methylation levels of the CpG motif at -
74 bp were lower in patients with chronic periodontitis (CP)
and RA than in healthy controls [27]. It has also been dem-
onstrated that levels of serum IL-6 and IL-6 production by
PBMCs were different between individuals with and without
the methylation at -74 bp [27]. These results suggest that the
hypomethylated status of a single CpG in the IL-6 promoter
region leads to increased levels of serum IL-6, implicating a
role in the pathogenesis of CP and RA.
Gene association studies are of limited value, despite their
effectiveness in detecting genes underlying common andmore
complex diseases such as periodontitis where the genetic risk
is relatively small [28, 29]. The first major concern related to
many of the gene association studies carried out to date is that
relatively small size of the participants, which results in a large
potential false-positive and false-negative results, and exhibit
a lack of statistical power to properly detect association.
Another important issue is the difficulty in defining the disease
phenotypes. It is difficult to distinguish AgP from CP due to
their similarities in the clinical symptoms, which makes inter-
pretation and replication of the case-control studies difficult. A
third concern is that the study participants should be carefully
matched to ethno-geographic origin, because the frequencies
of genotype and allele may have ethnic heterogeneity. For
example, frequencies of the rare allele in the IL-1A +4845,
IL-1B +3954, and IL-1 variable number of tandem repeats
genes are extremely low in Asian in contrast to white popula-
tions [28]. Furthermore, it should be emphasized that such
association studies only assess the candidate risk genes select-
ed according to the hypotheses based on the molecular bio-
logical mechanisms, but may overlook other genes involved in
the host responses. Collectively, it would be more effective to
apply a hypothesis-free approach, genome-wide association
study (GWAS) to enable the parallel screening of common
risk genes in relation to periodontitis and RA [30•, 31, 32].
Genome-Wide Association Study (GWAS)
Despite performing many different GWAS for almost all
human diseases, only three GWAS have been reported in
relation to periodontitis [33–35]. In 2010, the first GWAS
demonstrated an association of the glycosyltransferase 6 do-
main containing one gene on chromosome 9q34.3 with AgP,
which was repeatedly replicated through a clinical network
across Germany (283 AgP and 972 control) and the Nether-
lands (164 AgP and 368 control) [33]. It has also been dem-
onstrated that the rare allele of SNP rs 1537415 resulted in an
impaired binding of the transcription factor, GATA binding
protein 3 (GATA-3), which is related to the transcriptional
control of T-helper 2 cell differentiation. These results suggest
that this locus constitutes an important susceptibility factor,
and that GATA-3 is a potential signaling component in the
pathophysiology of AgP. The second GWAS conducted in 2,
681 patients with CP and 1,823 control individuals of Amer-
icans of European ancestry did not identify any specific gene
and locus in relation to CP [34], which is consistent with the
results of the third GWAS assessing 4,032 German individuals
with mixed periodontal condition, ranging from no or mild CP
to moderate and severe CP [35].
On the other hand, two large meta-analyses of GWAS have
been performed for identification of RA risk loci independent-
ly in different populations [31, 32]. The first large meta-
analysis of GWAS was conducted in 5,539 autoantibody-
positive individuals with RA and 20,169 controls of European
descent, followed by replication of in an independent set of 6,
768 RA cases and 8,806 controls [31]. In these analyses, seven
new RA risk alleles, i.e. IL6ST, SPRED2, RBPJ, CCR6, IRF5,
and PXK, were identified at genome-wide significance, and
three associated RA risk loci, i.e. IL2RA, CCL21, and AFF3,
were refined [31]. The second large meta-analysis of GWAS
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was conducted in a Japanese population including 4,074
individuals with RA and 16,891 controls, followed by a
replication in 5,277 RA cases and 21,684 controls [32]. These
analyses identified nine loci newly associated with RA, which
includes B3GNT2, ANXA3, CSF2, CD83, NFKBIE, ARID5B,
PDE2A-ARAP1, PLD4, and PTPN2 [32]. In addition, a multi-
ancestry comparative analysis of 46 risk loci conducted be-
tween the above-mentioned Japanese and European descents
showed a significant association with RA at 22 loci in Japa-
nese and at 36 loci in Europeans, with 14 loci being shared
between the populations [32].
Collectively, these observations suggest difficulties in iden-
tifying common genetic risk factors for periodontitis and RA,
despite a large number of genetic case-control studies and
GWAS in individuals with both diseases. In the future, it will
be necessary to identify causal genetic variants and their
functional characterization, which might be achieved by use
of new technologies and innovative research strategies.
Common Pro-inflammatory Cytokines
Periodontitis and RA have been suggested to exhibit a com-
mon pathophysiology characterized by persistent high levels
of pro-inflammatory cytokines and reduced levels of anti-
inflammatory mediators in the compartment adjacent to bone
[5]. In particular, it has been suggested that the excess pro-
duction and release of pro-inflammatory cytokines including
TNF-α and IL-6 are involved in the soft and hard tissue
destruction in both inflammatory diseases [36–39].
TNF-α and Related Receptors
TNF-α plays a critical role in the host response against a wide
range of bacterial infections, which contributes to both innate
and adaptive immune response [40, 41]. The majority of
antimicrobial and inflammatory effects of TNF-α are mediat-
ed through the TNF-α receptor p55, whereas TNF-α signaling
through the p75 receptor acts to attenuate the inflammatory
response [42]. A number of animal studies have indicated a
significant role for TNF-α in the alveolar bone loss that is a
main characteristic of periodontitis [36, 37, 43–45]. It has
been reported that Porphyromonas gingivalis-induced osteo-
clastogenesis is reduced in mice deficient in TNF-α receptor
p55 and p75 compared to wild-type mice [43]. This suggests
that osteoclast formation resulted from stimulation of the host
response rather than from the direct effect of bacterial prod-
ucts. In particular, TNF-α receptor p55-knockout mice devel-
op a less severe periodontitis in response to oral infection with
Aggregatibacter actinomycetemcomitans (previously
Actinobacillus actinomycetemcomitans), characterized by less
alveolar bone loss and inflammatory reaction compared with
wild-type controls [44]. Furthermore, subcutaneous
administration of recombinant human TNF-α accelerates the
progression of experimental periodontitis [45].
With regard to human periodontitis, an immunohistochem-
istry study showed increased levels of TNF-α receptor p55 and
p75 expression and TNF-α positive cells in the gingival tissue
from patients with adult periodontitis comparedwith the healthy
controls [46]. In addition, the concentration of TNF-α in gingi-
val crevicular fluid (GCF) from patients with CP and AgP were
higher than those in GCF from healthy control individuals [47].
Furthermore, the total amounts of TNF-α and soluble TNF
receptor 1 and 2 in GCF elevated with increasing probing depth
(PD) in both site-based and subject-based analyses [48]. These
results obtained from both animal and human studies demon-
strate clearly that TNF-α plays a central role in the host inflam-
matory reaction, which is related to the breakdown of alveolar
bone as well as loss of connective tissue attachment.
The significant role of TNF-α in the pathogenesis of RA
has been well documented [38, 39]. Relevance of TNF-α to
periodontal inflammatory condition has also been implicated
in patients with RA [49–51]. TNF-α levels in unstimulated
whole blood cell culture were higher in patients with RA than
those in healthy controls [49]. Serum levels of TNF-α were
increased in patients with RA than those in age-, gender-,
smoking status-, and periodontal condition-balanced control
individuals [50]. Interestingly, it was shown that serum levels
of TNF-α was positively correlated with RA activity and
bleeding on probing (BOP) in patients with RA [50]. More-
over, RA patients with high plasma levels of time-averaged
TNF-α had a higher frequency of BOP as well as increased
PD and clinical attachment level (CAL) compared with those
with low plasma levels of TNF-α [51]. These observations
suggest that periodontal inflammation may be related to high
levels of systemic and local TNF-α in patients with RA.
IL-6 and Signaling Mediators
IL-6 is a multifunctional pro-inflammatory cytokine that has a
wide range of biological activities in various target cells and
regulates immune responses, acute phase reactions, hemato-
poiesis, and bone metabolism [52, 53]. IL-6 signaling is
mediated through two functional membrane proteins: an
80 kDa ligand-binding chain (IL-6 receptor [IL-6R], IL-6R
α-chain, or CD126) [54] and a 130 kDa non-ligand-binding
signal-transducing chain (glycoprotein 130 [gp130], IL-6R β-
chain, or CD130) [55]. In cells with sufficient membrane-
bound IL-6R, IL-6 binds to these receptors, followed by the
IL-6/IL-6R complex induced-homodimerization of the gp130
molecule, and forms a high-affinity functional receptor com-
plex IL-6/IL-6R/gp130 [56]. However, under insufficient cell-
surface IL-6R, IL-6 signal transduction starts with the binding
of IL-6 to the free soluble IL-6R (sIL-6R), which lacks the
membrane and intracytoplasmic portion of the membrane-
bound IL-6R molecule [55, 56].
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Several studies have reported the systemic and local produc-
tion of IL-6 and its signaling mediators in patients with periodon-
titis [57, 58•]. High levels of IL-6-specific mRNA have been
observed in gingival mononucliar cells (GMCs) from patients
with adult periodontitis [59]. IL-6 protein is also produced in the
culture supernatants of GMCs, but not in those of PBMCs in the
same patients [59]. Furthermore, the expressions of mRNA for
IL-6, IL-6R, and gp130, as well as those of proteins for IL-6 and
sIL-6R can be detected in inflamed gingival tissue [60, 61]. In
accordance with these findings, expressions of IL-6-specific
mRNA and protein can be detected in human periodontal liga-
ment fibroblasts and gingival fibroblasts upon stimulation with
lipopolysaccharides from periodontopathic bacteria such as
P. gingivalis and A. actinomycetemcomitans [62–64]. It has also
been documented that systemic (serum) and local (GCF and
saliva) levels of IL-6 are increased in patients with periodontitis
than those in the healthy controls [65–68]. Serum levels of IL-6
appear to be reduced after intensive periodontal treatment includ-
ing oral hygiene instruction, subgingival scaling, and root planing
[68–70].
The pathological role of IL-6 has been documented in patients
with RA as well [38, 39]. It has been documented that a trend
toward increase in GCF levels of IL-6 was observed in patients
with RA [71]. Increased levels of IL-6 were also observed in
unstimulated whole blood cell culture of patients with RA com-
pared with those of the healthy controls [49]. Another study
indicated that serum levels of IL-6 were higher in patients with
RA than those in age-, gender-, smoking status-, and periodontal
condition-balanced healthy control individuals, and also showed
that serum levels of IL-6 were positively correlated with RA
activity [50]. These observations suggest that systemic and local
produced IL-6 may play a role in regulating periodontal inflam-
mation in patients with RA.
Cytokine-Targeted Therapies
It has been well recognized that both periodontitis and RA are
associated with persistent high levels of pro-inflammatory
cytokines including TNF-α, IL-1, and IL-6 [4, 5, 36–39]. This
leads to the hypothesis that pro-inflammatory cytokine-
targeted pharmacologic treatment may reduce systemic and
local levels of these cytokines, and concomitantly improve
periodontal inflammatory condition. Novel therapeutic strate-
gies based on TNF-α and IL-6 blockade have been developed,
and are currently used for the treatment of RA [72•, 73]. To
date, there have been several studies evaluating in vitro and
in vivo efficacy of TNF-α- and IL-6R-targeted therapies in the
treatment of periodontitis.
Animal Studies
Significant inhibitory effects of IL-1 and TNF antagonists on
periodontal inflammatory and destructive responses have been
demonstrated in a Macaca fascicularis primate model of
experimental periodontitis [74]. The results indicated that injec-
tion of soluble receptors to IL-1 and TNF inhibited by approx-
imately 80 % the recruitment of inflammatory cells in close
proximity to bone, and also reduced the formation of osteoclasts
by 67% and the amount of bone loss by 60%, respectively [74].
Likewise, blockade of IL-1 and TNF resulted in an inhibitory
effects on the progression of inflammatory cell infiltration toward
alveolar bone in the same animal model [75]. In addition, the
histomorphometric analysis indicated that IL-1 and TNF antag-
onists reduced the loss of connective tissue attachment by ap-
proximately 51 % and the loss of alveolar bone height by almost
91 % in the same experimental periodonttiis model [76]. How-
ever, the effects of local injection of IL-1 and TNF soluble
receptors proved different between the early and late phases of
periodontal wound healing in a non-human primate model [77].
Short-term blockade of IL-1 and TNF may facilitate periodontal
wound healing, whereas the prolonged blockade may have ad-
verse effects [77]. Furthermore, recent studies showed that anti-
TNF-α antibody treatment improved the host response to
Porphyromonas gingivalis and was related to reduced serum
levels of TNF-α and IL-6 in mice [78, 79].
Human Trials
The effect of cytokine-targeted therapy on periodontal condi-
tion in patients with RA has been reported in several studies
[80–85, 86••]. A summary of studymethods and results obtained
from each study are presented in a chronological order (Table 1).
First, Pers et al. evaluated periodontal condition in 20 French
patients with RAwho had received infliximab (IFX, a chimeric
mouse/human anti-TNF-αmonoclonal antibody) every 6 weeks
for more than 22 months and 20 race-, age-, gender-, and
smoking status-balanced patients with RAwho had not received
IFX medication [80]. Of 20 patients in the control group, nine
were subjected to assessment before and after IFX therapy. The
results showed that IFX increased modified gingival and papil-
lary bleeding indices and decreased attachment loss, but did not
affect PD [80]. The second comparative clinical study conducted
by Oritz et al. reported that medication of TNF inhibitors includ-
ing IFX, etanercept (ETN, a recombinant fusion protein linked to
human type II TNF receptor-Fc portion), or adalimumab (ADA,
a fully humanized anti-TNF-αmonoclonal antibody) resulted in
an improvement of gingival index (GI), BOP, PD, and CAL,
which is only shown with periodontal therapy [81]. Mayer et al.
indicated that patients with RA who received IFX had lower
periodontal indices and GCF TNF-α levels [82, 83]. In addition,
Üstün et al. showed that TNF inhibitors such as IFX and ADA
decreased periodontal inflammatory indices, and also lowered
GCF levels of IL-1 β and IL-8, and saliva levels of IL-8 and
monocyte chemoattractant protein-1 [84]. Recently, Kobayashi
et al. demonstrated a beneficial effect of ADA therapy on peri-
odontal inflammatory condition in patients with RA [85]. It was
proposed that this might be related to decrease in serum levels of
CRP, matrix metalloproteinase-3 (MMP-3), IL-6, TNF-α, and
acute phase proteins [85]. On the other hand, there has been only
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one study assessing IL-6R inhibition therapy with tocilizumab
(TCZ, a humanized monoclonal anti-human IL-6R antibody
with specificity for the soluble and membrane-expressed IL-
6R) on periodontal condition in patients with RA and CP
[86••]. The results showed that the patients with RA who re-
ceived TCZ exhibited a greater decrease in GI, BOP, PD, CAL,
and serum levels of IL-6 and MMP-3 than the control patients
[86••].
Conclusions
It has been recognized for some time that periodontitis and RA
share many common pathologic features, which may be based
on the similarities in host response. In particular, constitutive
overproduction of pro-inflammatory cytokine, TNF-α, and
IL-6 has been implicated as one of the most common con-
founding factors for the two inflammatory diseases. Results
from animal and clinical intervention studies have suggested
an improvement of periodontal inflammatory condition after
treatment with TNF-α and IL-6 receptor inhibitors. However,
the clinical studies carried out to date have had very low
numbers of subjects and short time for observation. Therefore,
more extensive studies in a larger patient group would be
necessary to better assess the therapeutic efficacy of pro-
inflammatory cytokine blockade on periodontitis.
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